Paige, a Sloan-Kettering spinout, is leader in computational pathology which is transforming the diagnosis and treatment of cancer.
Paige has been building an artificial intelligence platform to improve cancer pathology and subsequently use those insights to develop better drug therapies.
Paige was founded in 2017 by Dr. Thomas Fuchs and colleagues from Memorial Sloan Kettering Cancer Center. The company is headquartered in Franklin D Roosevelt Island, New York.
Paige has created an AI-native ecosystem that enables pathology teams to achieve higher quality, faster throughput and lower cost diagnoses and treatment recommendations. Additionally, Paige accelerates new biomarker discovery and its platform is designed to generate new insights into pathways and drug efficacy.
Paige is the first company to receive FDA breakthrough designation for computational pathology products.
Paige is backed by Breyer Capital, Casdin Capital, Goldman Sachs Merchant Banking Division, KKR, JJDC, HealthCor Partners, Catalio Capital Management and others. The company added another $25M on Mar 09, 2021. This is an extension of their $100M Series C raised in Jan 2021, bringing the round to $125M. The additional investment brings Paige's total funding to $215M to date.